Its clinical use in acquired thrombotic thrombocytopenic purpura (TTP) demonstrates the therapeutic potential of directly targeting the vWF-ADAMTS13 axis in thrombotic disorders [75]. This evidence concerns the gene VWF and acquired thrombotic thrombocytopenic purpura.